{
    "cancelStatus": "0",
    "licStatus": "1",
    "cancelDate": null,
    "cancelReason": [],
    "otherCancelReason": "",
    "licid": "60001245",
    "licUnit": "1",
    "validDate": "2029-01-09 00:00:00.000",
    "issueDate": "2024-01-09 00:00:00.000",
    "oriIssueDate": "2024-01-09",
    "licKind": "04",
    "oldLicid": null,
    "certNo": "DHA06000124501",
    "prodNameC": "衛癌瑪注射液",
    "prodNameE": "Vegzelma concentrate for solution for infusion",
    "indicationsName": [
        "轉移性大腸直腸癌(mCRC)\r\n與含有5-fluorouracil為基礎的化學療法合併使用，可以作為轉移性大腸或直腸癌病人的第一線治療。\r\n與含有5-fluorouracil\/leucovorin\/oxaliplatin的化學療法合併使用，可以作為先前接受過以 fluoropyrimidine為基礎的化學療法無效且未曾接受過bevacizumab治療的轉移性大腸或直腸癌病人的治療。\r\n與含有fluoropyrimidine-irinotecan-或fluoropyrimidine-oxaliplatin-為基礎的化學療法合併使用，可以做為第一線已接受過Vegzelma 併用化療後惡化之轉移性大腸或直腸癌病人的第二線治療。\r\n轉移性乳癌(mBC) \r\n與paclitaxel合併使用，可以做為HER2 (-)轉移性乳癌病人的第一線治療。\r\n惡性神經膠質瘤(WHO第4級)-神經膠母細胞瘤\r\n單獨使用可用於治療曾接受標準放射線治療且含Temozolomide 在內之化學藥物治療失敗之多型性神經膠母細胞瘤(Glioblastoma multiforme)復發之成人病人。\r\n晚期、轉移性或復發性非鱗狀非小細胞肺癌(NSCLC)\r\n與carboplatin及paclitaxel合併使用，可以作為無法切除的晚期、轉移性或復發性非鱗狀非小細胞肺癌病人的第一線治療。\r\n併用erlotinib，可作為無法手術切除的晚期、轉移性或復發性且帶有表皮生長因子受體(EGFR)活化性突變的非鱗狀非小細胞肺癌病人的第一線治療。\r\n卵巢上皮細胞、輸卵管或原發性腹膜癌(Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer)\r\n與carboplatin及paclitaxel合併使用，接著單獨使用Vegzelma，可以做為第三期或第四期卵巢上皮細胞、輸卵管或原發性腹膜癌病人接受初次手術切除後之治療。\r\n與carboplatin及gemcitabine合併使用，可以做為曾接受過第一線含鉑類藥物(Platinum-based) 化學治療間隔至少6個月再復發 (即，對含鉑藥物具感受性)，且未曾接受過bevacizumab或其他血管內皮細胞生長因子 (VEGF) 抑制劑或血管內皮細胞生長因子接受器之標靶藥物 (VEGF receptor-targeted agents) 治療之復發性卵巢上皮細胞、輸卵管或原發性腹膜癌病人的治療。\r\n與carboplatin及paclitaxel合併使用，接著單獨使用Vegzelma治療，可以做為對含鉑藥物具感受性之復發性卵巢上皮細胞、輸卵管或原發性腹膜癌病人的治療。\r\n併用paclitaxel、topotecan或pegylated liposomal doxorubicin可以做為接受過含鉑類藥物 (platinum-based)化療治療後6個月內再復發(即，對含鉑藥物具抗藥性)、之前接受不超過2種化療療程且未曾接受過bevacizumab或其他血管內皮細胞生長因子(VEGF)抑制劑或血管內皮細胞生長因子接受器之標靶藥物(VEGF receptor-targeted agents)之復發性卵巢上皮細胞、輸卵管或原發性腹膜癌病人的治療。\r\n持續性、復發性或轉移性之子宮頸癌(Persistent, Recurrent, or Metastatic Cervical Cancer)\r\n與paclitaxel及cisplatin合併使用可用於治療持續性、復發性或轉移性之子宮頸癌。與paclitaxel及topotecan合併使用可用於無法接受含鉑類藥物治療(platinum therapy)病人之持續性、復發性或轉移性子宮頸癌。"
    ],
    "does": "227D",
    "packageUnit": [
        {
            "packageSpec": "4毫升及16毫升(type I glass)",
            "packageUnit": "L2"
        },
        {
            "packageSpec": "100支以下",
            "packageUnit": "03"
        }
    ],
    "medMCode": "05",
    "maMedCode": "",
    "medDCode": "D",
    "mainCategory": "D",
    "drBaseId": "9F5DB2BF-34A3-4DDD-AB09-5F7B66CD08F2",
    "subCategory": [
        "D"
    ],
    "ingredientsDesc": [
        "BEVACIZUMAB"
    ],
    "restraintItemsCode": [
        "02 輸 入",
        "1D 須執行風險管理計畫",
        "91 生物相似性藥品"
    ],
    "applicantName": "台灣賽特瑞恩有限公司",
    "applicantAddr": "臺北市信義區松仁路97號3樓之1",
    "medClass": null,
    "efficacy": " ",
    "mdFormat": null,
    "productAnnotation": "",
    "mdKind": [],
    "monitorDate": "2029-01-09",
    "licidNew": null,
    "licidOld": null,
    "manuImportDesc": "廠商未登錄資料",
    "licManuImport": "2",
    "factoryDtoList": [
        {
            "id": "8B814674-C94D-4D34-BEFC-270284804B3E",
            "factoryCode": "1",
            "factoryName": "CELLTRION INC.",
            "factoryAddr": "20, ACADEMY-RO, 51BEON-GIL, YEONSU-GU, INCHEON, 22014, REPUBLIC OF KOREA",
            "factoryCompanyAddr": null,
            "countryCode": "KR",
            "processCode": [
                {
                    "value": "2I",
                    "name": "原料藥及成品製造廠"
                }
            ],
            "processCodeStr": "2I;原料藥及成品製造廠",
            "factoryKind": "M",
            "factoryNo": "FKR0182100",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        }
    ],
    "ingredientsDtoList": [
        {
            "ingredientsKind": "1",
            "ingredientsCode": "1013000800",
            "ingredientsName": "BEVACIZUMAB",
            "ingredientsDesc": "BEVACIZUMAB",
            "concentDesc": "",
            "concent": "25.000000",
            "concentUnit": "001",
            "seq": "1",
            "prescription_seq": "1",
            "prescription_Kind": "1"
        }
    ],
    "authDtoList": [],
    "iomDtoList": [],
    "changeDtoList": [],
    "atcList": [
        {
            "isMain": "1",
            "atcCode": "L01FG01"
        }
    ],
    "licBaseId": "FDC41A09-BC03-4F74-9B5C-07F2E8C71C4B"
}